Protocol Ledger

NCT04887831 · Phase II · TERMINATED

Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab

Interventional Phase II clinical trial protocol NCT04887831 sponsored by G1 Therapeutics in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-06-04 Enrollment: 92 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04887831
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)92 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04887831
Protocol FieldVerified Registry Value
NCT IdentifierNCT04887831
Consolidated Lead SponsorG1 Therapeutics
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment92 participants (ACTUAL)
Registered Start Date2021-06-04
WhyStopped ClassificationUnspecified

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI